Weekend discharge not associated with increased readmission rate
the ONA take:
According to a study published online in the Journal of Hospital Medicine, researchers from Stanford University in California have found that for patients with acute myocardial infarction, congestive heart failure, or pneumonia, weekend discharge is not linked with 30-day readmission.
For the study, researchers analyzed data from 266,519 patients with acute myocardial infarction, congestive heart failure, or pneumonia from the 2012 California Office of Statewide Health Planning and Development database. Of those patients, 22.5% were discharged during the weekend.
Results showed that the unadjusted 30-day hospital readmission rates were similar for weekend and weekday discharges across all three patient groups. Moreover, weekday discharge was associated with with longer length of stay and more frequent discharge from the hospital to a skilled nursing facility.
"In conclusion, among patients admitted with AMI, CHF, or pneumonia in California, discharge on a weekend is not associated with hospital readmission," the authors conclude. "Future studies on hospital readmissions should use a population-based approach to accurately capture all readmissions following discharge."
For patients with acute MI, CHF, or PNA, weekend discharge is not linked with 30-day readmission.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|